Mini-Oral Abstract Session: Immunosuppression and Tolerance 2
Wednesday October 01, 2025 from 16:20 to 17:10
Auditorium
Lectures
-
ModeratorDr. Hidetaka Hara, People's Republic of China
-
ModeratorYannick Muller, Switzerland
-
210.1 Ex vivo pig liver xenoperfusion with human red blood cells and mesenchymal stem cells to enhance the endothelial barrier function and attenuate inflammationDr. Anjali Verma, United States
-
210.2 Application of immunosuppressive regimen in xenotransplantation of gene-edited porcine heart to rhesus macaqueDr. Huan Wang, People's Republic of China
-
210.3 Gut microbiota metabolite L-Histidine (L-His) alleviates tacrolimus-induced islet dysfunction post-transplantation via IRS-2/Akt/mTOR/FOXO1 signaling pathwayYi Wang, People's Republic of China
-
210.4 Generation and functional assessment of human cytotoxic T cells directed against wild-type and genetically modified pig endothelial cellsViktoriia Galdina, Switzerland
-
210.5 Immortalized aortic endothelial cells from genetically modified pigs for evaluation of human‑to‑pig xenoreactive immune responsesDr. Man Zhang, People's Republic of China
-
210.6 KJ047 is a next generation CD40 ligand antibody designed for safe and durable immunosuppression in combination with IgG degrading enzymesMs. Yunxia (Erica) Xu, People's Republic of China
-
210.7 Early mixed chimerism after pig to non-human primate liver xenotransplantationDr. Sho Fujiwara, United States